COVID-19 Top News – March 25, 2020

March 25, 2020

FDA now allows treatment of life-threatening Covid-19 cases using blood from patients who have recovered (TechCrunch) – Mar 25, 2020 – “The U.S. Food and Drug Administration (FDA)…include use of ‘convalescent plasma’, in cases where the patient’s life is seriously or immediately threatened. This isn’t an approval of the procedure as a certified treatment, but rather an emergency clearance that applies only on a case-by-case basis, and only in extreme cases….FDA has granted this temporary authorization under its Investigational New Drug Applicants (eINDS) exemption.”


Study tests proven blood clot buster against Covid-19 (Drug Discovery & Development) – Mar 25, 2020 – “In a clinical trial being planned for hospitals in Massachusetts and Colorado, patients with severe cases of COVID-19 would be given the blood thinner tissue plasminogen activator (tPA), a protein prescribed for heart attack and stroke victims….The researchers will test tPA in patients under the FDA’s ‘compassionate use’ program….BARDA ( the Biomedical Advanced Research and Development Authority) will fund the trial. Genentech is donating the drug for the initial trial.”


remdesivir (GS-5734) / Gilead
Lives are on the line: Science matters in finding coronavirus treatments (NBC News) – Mar 25, 2020 – “In Nebraska, researchers are studying whether an experimental drug, remdesivir, can treat COVID-19, the illness that results from coronavirus infection.”


trabedersen (OT-101) / Autotelic, Mateon Therapeutics
Mateon report positive results for multiple COVID-19 drug candidates (GlobeNewswire) – Mar 25, 2020 – “OT-101 continued to show significant activity against coronaviruses and in the new testing results, two additional therapeutic oligonucleotides designed to target COVID-19 also demonstrated potent anti-viral activity….OT-101 and the other candidates work by inhibiting virus binding to its target, thereby stopping the virus from replicating itself and stopping viral induced pneumonia, which often leads to patient complications….The Company has begun preparations to submit an Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) for OT-101 against COVID-19 to expedite testing in COVID-19 patients.”


BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat Covid-19. Laboratory results demonstrate high level of activity against Covid-19 in cell culture (GlobeNewswire) – Mar 25, 2020 – “BioSig Technologies, Inc…acquired the rights to develop a novel pharmaceutical to treat Coronavirus Disease 2019 (COVID-19)….Anti-viral agent Vicromax(tm) demonstrated strong activity against COVID-19 in cell cultures in laboratory testing….The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials….The Company intends to develop Vicromax(tm) and take it through clinical trials under a new NeuroClear subsidiary, ViralClear Pharmaceuticals, Inc.”


CytoSorb used to treat more than 70 critically-ill Covid-19 patients and specifically added to coronavirus treatment guidelines in Italy and Panama (PRNewswire) – Mar 25, 2020 – “CytoSorb use has generally been associated with a marked reduction in cytokine storm and inflammation, improved lung function, weaning from mechanical ventilation, and a reversal of shock. Certainly not all treatments have been successful in this critically-ill patient population that verges on death, particularly when used too late.”


Nu-Med Plus closely monitoring outcomes on two new human clinical trials using inhaled nitric oxide in treatment of Covid-19 (GlobeNewswire, Nu-Med Plus Inc.) – Mar 25, 2020 – “Nu-Med Plus, Inc…today announced that the Company is closely monitoring two new clinical trials that are testing Nitric Oxide Gas Inhalation Therapy for the treatment of mild/moderate COVID-19….Data on SARS-CoV suggest that iNO could have a similar effect on COVID-19 due to the genomic similarities between the two coronaviruses.”


Eurobio Scientific gets CE marking for its proprietary COVID-19 test (GlobeNewswire) – Mar 25, 2020 – “Eurobio Scientific…is today announcing the CE marking for its EBX 041 SARS CoV2 proprietary test, developed specifically for the clinical diagnosis of COVID-19. The EBX 041 SARS CoV2 proprietary kit follows the design recommended by the French National Reference Center (CNR) and has been approved based on clinical samples with an independent hospital. This is a multiplex kit with three targets: two for identifying the virus and one target for a control integrated into each patient test.”


Sorrento Launches Novel I-Cell COVID-19 Cellular Vaccine Program (GlobeNewswire, Sorrento Therapeutics, Inc.) – Mar 25, 2020 – “STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus….The I-Cell vaccine is expected to elicit both T cell and B cell immunities against SARS-CoV-2.”

No Comments

Post a Comment